Literature DB >> 10402368

Variation of luteinizing hormone and androgens in oligomenorrhoea and its implications for the study of polycystic ovary syndrome.

M H van Hooff1, M van der Meer, C B Lambalk, J Schoemaker.   

Abstract

We measured luteinizing hormone (LH) and androgen concentrations in patients at different phases of the oligomenorrhoeic cycle and compared the results with those of patients with normogonadotrophic amenorrhoea. Several blood samples separated by >/=7 days were obtained from each of 72 patients with oligomenorrhoea and 18 with normogonadotrophic amenorrhoea. The oligomenorrhoeic cycle was divided into five phases: the postmenstrual phase week 1 (day 1-7) and week 2 (day 8-14), the specific oligomenorrhoeic phase (SOP, day 15 after a menstruation to day 21 before the next menstruation), the possibly peri-ovulatory phase (days 21-11 before menstruation) and the premenstrual phase (days 10-1 before menstruation). Samples obtained in the possibly peri-ovulatory phase were excluded. Within individuals LH concentrations were significantly higher during the SOP than during all other phases of the oligomenorrhoeic cycle (paired t-test, P = 0.0001-0.03). In contrast to the other phases of the oligomenorrhoeic cycle, no significant differences in gonadotrophins, androgen or oestradiol concentrations were found between the SOP and normogonadotrophic amenorrhoea. In oligomenorrhoea timing of blood sampling influences the measurement of LH and androgen concentrations, and the accurate interpretation of these measurements requires that the dates of menstruation both before and after the sample is taken should be known. In patients with oligomenorrhoea blood samples should be obtained during the SOP, when the endocrinology is comparable with that of normogonadotrophic amenorrhoea.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10402368     DOI: 10.1093/humrep/14.7.1684

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  3 in total

1.  Ovarian steroids modulate neuroendocrine dysfunction in polycystic ovary syndrome.

Authors:  S A R Doi; M Al-Zaid; P A Towers; C J Scott; K A S Al-Shoumer
Journal:  J Endocrinol Invest       Date:  2005-11       Impact factor: 4.256

2.  LH suppression following different low doses of the GnRH antagonist ganirelix in polycystic ovary syndrome.

Authors:  F P Hohmann; J S E Laven; A G M G J Mulders; J J L Oberyé; B M J L Mannaerts; F H de Jong; B C J M Fauser
Journal:  J Endocrinol Invest       Date:  2005-12       Impact factor: 4.256

3.  Does measuring early basal serum follicular luteinising [correction of lutinising] hormone assist in predicting in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) outcome?

Authors:  Ahmed Kassab; Luca Sabatini; Gidon Lieberman; Amanda Tozer; Ariel Zosmer; Colin Davis; Talha Al-Shawaf
Journal:  Reprod Biol Endocrinol       Date:  2007-07-20       Impact factor: 5.211

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.